Coloplast Revises Financial Guidance for FY 2025/26

Coloplast A/S has updated its financial outlook for FY 2025/26, lowering its organic growth expectation from approximately 7% to 5-6% and EBIT growth from about 7% to around 5%. This revision is due to a slower market recovery in skin substitutes, particularly for Kerecis, which also saw an impairment loss of DKK 3 billion impacting its goodwill valuation. Coloplast will hold an extraordinary conference call regarding this guidance change.